Pfizer Receives Positive Results for Menopause Drug Pristiq

Pfizer has published clinical trial data that supports the effectiveness of its drug Pristiq for the treatment of hot flashes in postmenopausal women.

Pfizer has received positive results from a Phase III study of Pristiq (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor that reduces the number and severity of moderate-to-severe hot flashes in postmenopausal women.

The double-blind, placebo-controlled study involved 365 patients, and found that desvenlafaxine met all the co-primary endpoints, showing a reduction in hot flash frequency.

Adverse affects with the use of drug include nausea, dry mouth, fatigue, constipation, diarrhoea and drowsiness.

The drug is under review by the US Food and Drug Administration for the treatment of moderate-to-severe vasomotor symptoms associated with menopause